AbbVie Expects Week-16 HS Readouts and SKYRIZI SubQ Data This Year
AbbVie outlined year-end week-16 double-blind readouts for lutikizumab and RINVOQ in hidradenitis suppurativa, highlighting strong phase-2 results in TNF-experienced and treatment-naive cohorts and a dual IL-1 alpha/β blockade strategy. The company also previewed subcutaneous SKYRIZI data due this year and detailed IBD combination trials and next-gen immunology platforms.
1. HS Clinical Milestones
AbbVie plans double-blind week-16 data by year-end for lutikizumab (IL-1α/β bispecific) and RINVOQ in hidradenitis suppurativa, citing strong phase-2 efficacy in both TNF-experienced and treatment-naive populations and supporting the rationale for dual IL-1 blockade to target neutrophil-driven disease.
2. IBD Combination Roadmap
The company previewed subcutaneous SKYRIZI data due this year and outlined combination studies pairing SKYRIZI with alpha-4 beta-7, TL1A, lutikizumab and TREM1 to enhance efficacy, durability and remission rates in ulcerative colitis and Crohn’s disease, leveraging front-line share and potential co-formulations.
3. Next-Gen Immunology Platforms
AbbVie highlighted advancement of an oral IL-23 program through Nimble, a CD19 ADC (319), ABBV-519 and a partnered in-situ LNP CAR-T approach, emphasizing goals of higher potency, durability and anti-fibrotic activity across its immunology pipeline.
4. Competitive and Biomarker Considerations
Executives addressed immunogenicity challenges with anti-TNF bispecifics, reaffirmed the importance of dual IL-1 alpha/beta targeting, and emphasized ongoing biomarker collection and TL1A’s potential anti-fibrotic applications in broader indications such as arthritis and sclerosis.